Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31376053 | 0.91 | TSHR (0.46) | TSHRHSD17B10HPGDCYP3A4ALDH1A1 | |
| SCHEMBL29381344 | 0.79 | AHR (0.40) | CA1CA2CA9AHR | |
| SCHEMBL21356327 | 0.79 | AHR (0.40) | CA1CA2CA9AHR | |
| SCHEMBL29720512 | 0.77 | TSHR (0.60) | TSHRHSD17B10HPGDCYP3A4ALDH1A1 | |
| SCHEMBL305189 | 0.77 | TSHR (0.60) | TSHRHSD17B10HPGDCYP3A4ALDH1A1 | |
| SCHEMBL8640677 | 0.77 | TSHR (0.52) | TSHRHSD17B10HPGDCYP3A4ALDH1A1 | |
| SCHEMBL1425452 | 0.77 | HSD17B10 (0.60) | TSHRHSD17B10HPGDCYP3A4ALDH1A1 | |
| SCHEMBL8820666 | 0.75 | TSHR (0.57) | TSHRHSD17B10HPGDCYP3A4ALDH1A1 | |
| SCHEMBL2215984 | 0.75 | TSHR (0.57) | TSHRHSD17B10HPGDCYP3A4ALDH1A1 | |
| SCHEMBL7594838 | 0.72 | HSD17B10 (0.60) | TSHRHSD17B10HPGDCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-10442804-B2 | Compounds for the treatment of hepatitis B virus infection | GILEAD SCIENCES, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10100052-B2 | — | — | 2018-10-16 | — | — | US | disclosed |
| US-20180251460-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2018-09-06 | — | — | US | disclosed |
| WO-2018144605-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144605-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2017205115-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205115-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251460-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | HAVCR2, PYGL, OAT | TSHR 3818/4885HSD17B10 436/4885HPGD 615/4885 |
| US-10100052-B2 | — | HAVCR2, PYGL, FABP1 | TSHR 3865/4885HSD17B10 556/4885HPGD 1046/4885 |
| US-10442804-B2 | Compounds for the treatment of hepatitis B virus infection | HAVCR2, PYGL, OAT | TSHR 3818/4885HSD17B10 436/4885HPGD 615/4885 |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TSHR 2377/4885HSD17B10 1464/4885HPGD 823/4885 |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | HAVCR2, PYGL, OAT | TSHR 3818/4885HSD17B10 436/4885HPGD 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.